Stockreport

Celgene and Acceleron's luspatercept successful in late-stage beta thalassemia study [Seeking Alpha]

CELGENE  (CELG) 
Last celgene earnings: 10/31 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: ir.celgene.com
PDF A Phase 3 clinical trial, BELIEVE , evaluating Celgene (NASDAQ: CELG ) and Acceleron Pharma's (NASDAQ: XLRN ) luspatercept in adults with beta-thalassemia-assoc [Read more]